Identification of Functional SNPs in BARD1 Gene and In Silico Analysis of Damaging SNPs: Based on Data Procured from dbSNP Database

Ali A. Alshatwi1*, Tarique N. Hasan1,2, Naveed A. Syed1, Gowhat Shafi3, B. Leena Grace3

1 Molecular Cancer Biology Research Laboratory, Department of Food Science and Nutrition, King Saud University, Riyadh, Saudi Arabia, 2 Research and Development Center, Bharathiar University, Coimbatore, Tamil Nadu, 3 Department of Biotechnology, Vinayaka Missions University, Salem, Tamil Nadu

Abstract

Background: The BARD1 gene encodes for the BRCA1-associated RING domain (BARD1) protein. Germ line and somatic mutations in BARD1 are found in sporadic breast, ovarian and uterine cancers. There is a plethora of single nucleotide polymorphisms (SNPs) which may or may not be involved in the onset of female cancers. Hence, before planning a larger population study, it is advisable to sort out the possible functional SNPs. To accomplish this goal, data available in the dbSNP database and different computer programs can be used. To the best of our knowledge, until now there has been no such study on record for the BARD1 gene. Therefore, this study was undertaken to find the functional nsSNPs in BARD1.

Result: 2.85% of all SNPs in the dbSNP database were present in the coding regions. SIFT predicted 11 out of 50 nsSNPs as not tolerable and PolyPhen assessed 27 out of 50 nsSNPs as damaging. FastSNP revealed that the rs58253676 SNP in the 3’ UTR may have splicing regulator and enhancer functions. In the 5’ UTR, rs17489363 and rs17426219 may alter the transcriptional binding site. The intronic region SNP rs67822872 may have a medium-high risk level. The protein structures 1JM7, 3CSR and 2NTE were predicted by PDBSum and shared 100% similarity with the BARD1 amino acid sequence. Among the predicted nsSNPs, rs4986841, rs111367604, rs13389423 and rs139785364 were identified as deleterious and damaging by the SIFT and PolyPhen programs. Additionally, I-Mutant showed a decrease in stability for these nsSNPs upon mutation. Finally, the ExPasy-PROSIT program revealed that the predicted deleterious mutations are contained in the ankyrin ring and BRCT domains.

Conclusion: Using the available bioinformatics tools and the data present in the dbSNP database, the four nsSNPs, rs4986841, rs111367604, rs13389423 and rs139785364, were identified as deleterious, reducing the protein stability of BARD1. Hence, these SNPs can be used for the larger population-based studies of female cancers.

Background

A single-nucleotide polymorphism (SNP) is the most common type of genetic mutation. There are several publically available databases for SNPs, such as dbSNP, GWAS Central, SwissVar etc. dbSNP is the most extensive among all the databases. By release of 155 hosting number of human SNPs reached more than 50 million, including 535,660 synonymous and 873,308 non- synonymous SNPs [1]. Only the non-synonymous SNPs (nsSNPs), also called as missense variants are particularly important as they result in to changes in the translated amino acid residue sequence. It is likely that nsSNPs play a major role in the functional diversity of coded proteins in human populations and have been linked with many diseases. nsSNPs may affect the protein function by reducing protein solubility or by destabilizing protein structure and they may affect gene regulation by altering transcription and translation all in ways that may not be identified by structure or phylogeny-based features [2,3,4,5].

It is estimated that breast cancer may affect one out of every eight women at some point in her lifetime. Only 10% of women have a hereditary predisposition to breast cancer. Meanwhile, less than half of the patients have been found to carry a mutation in the BRCA1 or BRCA2 gene [6]. The disease may occur due to mutations in the code for the genes of the proteins that interact with BRCA1 and BRCA2. BARD1 is one of these genes and encodes the BRCA1-associated RING domain protein (BARD1). BARD1 is a protein with 777 residues. It contains an amino-terminal RING domain (residues 46–90), three ankyrin repeats (residues 427–525) and two carboxy-terminal BRCT domains (residues 616–653 and 743–777). It also has nuclear export and localization signals (residues 102–120 and the residues after 177, potentially residues 204–209) [7]. BARD1 makes a stable heterodimer in association with BRCA1 [8]. Many mutations have been identified in BARD1 in non-hereditary site-specific breast and breast/ovarian cancer cases [9,10]. The majority of
breast cancer cases (approximately 70%) are considered sporadic in nature because they do not have extensive familial history [11]. In most of these cases, BRCA1 and BRCA2 are rarely found mutated. In contrast, both germline and somatic BARD1 mutations are found in sporadic breast, ovarian and uterine cancers [12].

A somatic mutation (Val695Leu) and a germline mutation in BARD1 associated with sporadic breast cancer (Val695Leu) and one (Gln564His) associated with ovarian cancer have been reported [12]. Three SNPs namely, Lys312Asn, Cys557Ser and Gln564His associated with ovarian cancer have been reported to be involved into breast cancer susceptibility. Val507Met is considered to be responsible for high risk of postmenopausal breast cancer and Cys557Ser for familiar breast cancer [10,13]. In addition of the female specific cancers, BARD1 SNPs have been found to be associated with neuroblastoma. As a matter of fact, SNPs in BARD1 coding region cause the expression of an oncogenic isoform and that influence the neuroblastoma susceptibility and oncogenicity [14] (Bosse et al, 2012). BARD1 seems a plausible target for female-specific cancer and other cancer studies. However, knowledge about the clinical relevance for many of the BARD1 SNPs is still limited [9,10,12]. This study was undertaken to explore and extend the knowledge related to the effect of SNPs on the stability and function of the BARD1 gene.

Results and Discussion

The dbSNP database contains both validated and non-validated polymorphisms. In spite of this drawback, we opted to avail the dbSNP because allelic frequency of most of nsSNPs of BARD1 has been recorded there (except 12 out of 50) and that is the most extensive SNP database [15]. At dbSNP, BARD1 gene contains data for 1709 SNPs. Out of 1752 SNPs, 50 are nsSNPs and 14 are in UTRs. There are 6 SNPs in the 5’ UTR and 8 SNPs in the 3’ UTR. Our investigation accounted for the nsSNPs in the coding region and the 5’ and 3’ UTR SNPs. A graphical representation of the distribution of SNPs in the coding region and the UTRs is depicted in terms of percentage in Figure 1; 2.85% of the total numbers of SNPs are nsSNPs present in the coding region, whereas only 0.34% and 0.45% of the total number of SNPs are in the 5’ and 3’ UTRs, respectively.

Deleterious nsSNPs predicted by SIFT

The sequence homology-based tool SIFT was used to determine the level of conservation of a particular amino acid position in a protein. SIFT has been tested on many human SNP databases and was found able to distinguish the disease associated SNPs from a neutral one with only a 20% false positive error. The sensitivity of SIFT is confirmed by the subset of nsSNP from dbSNP predicted to affect function were involved in disease. Furthermore, The SIFT algorithm works mainly sequence for prediction while that performs similarly to tools that use structure. Since, SIFT can predict a large number of a substitutions, as that do not requires the structures. Seventy four percent (74%) of nsSNPs identified by the SNP Consortium, were sufficiently similar to homologs in protein sequence databases for SIFT prediction. Hence, using SIFT is advantageous over other tools [16].

A .txt file containing “db SNP rsIDs” of all 50 nsSNPs was submitted to the “SIFT” page (http://sift.jcvi.org/www/SIFT_dbSNP.html) to calculate the tolerance index. The functional impact of the amino acid substitution is inversely proportional to the tolerance index (TI), Figure 2 and Table 1 summarize the results. Out of 50 nsSNPs, 11 were predicted as ‘Not Tolerable’ (Table 1) and had a Tolerance Index (TI) ≤0.05. The corresponding amino acid substitutions of rs143914307, rs1040108, rs17579041, rs61754118 and rs13978364 had a TI score of 0.00. The TI score was 0.01 for rs187590561 and rs13399423, 0.02 for rs11367604, 0.03 for rs146629794 and 0.04 for rs3739885 and rs4986841. The nucleotide change G–T accounted for the maximum number (four) of deleterious SNPs, followed by A–G (two). The rest of the nucleotide changes occurred only once.

Figure 1. A graphical representation of distribution of nonsynonymous, 5’ UTR and 3’ UTR SNPs for BARD1 gene (based on the dbSNP database).

doi:10.1371/journal.pone.0043939.g001

Damaging nsSNPs predicted by PolyPhen

The nsSNPs involved in structural modification were determined by the PolyPhen (Polymorphism and Phenotype) program. PolyPhen software version 2.0.9 predicts the fate of the structure and function of a protein due to an amino acid change through specific empirical rules on the sequence. Input options for the tool are protein sequence, accession number or database ID/accession number combined with sequence position with amino acid variants. For sequence-based characterization of the substitution site PolyPhen uses the TMHMM algorithm, Coils2 program and SignalP program to predict transmembrane, coiled coil and signal peptide regions of the protein sequences. PolyPhen identifies homologues of the input sequences via a BLAST and calculates position-specific independent count (PSIC) scores for every variant and estimates the difference between the variant scores, the difference of >0.339 is detrimental. The program carries out a BLAST query of a sequence against a protein structure database (PDB and PQS) for mapping of the substitution site to known protein 3-dimensional structures. PolyPhen uses the DSSP database to obtain secondary structure and solvent accessible surface area for the mapped amino acid residues. There are certain empirical rules applied on the sequences and the accuracy of that is approximately 92% with a chance of 6% false positive prediction [17].

The protein accession number of BARD1 (Q99728) and the amino acid substitutions corresponding to each of fifty nsSNPs were submitted separately. Table 2 summarizes the results obtained from the PolyPhen server. A position-specific indepen-
dent count (PSIC) score difference was assigned using the categories ‘probably damaging’ (2.00 or more), ‘possibly damaging’ (1.40–1.90), ‘potentially damaging’ (1.20–1.50), ‘borderline’ (1.00–1.20) and ‘benign’ (0.00–0.90). Twenty-seven out of 50 nsSNPs were predicted as ‘damaging,’ and the PSIC scores fell into the range of 1.51 to 3.41. Five nsSNPs predicted to be deleterious by the SIFT program were also predicted to be ‘damaging’ by the PolyPhen server. rs139785364 had a SIFT TI of 0.00 and a PolyPhen PSIC of 2.495. Therefore, the relevant mutation would be important when manifesting itself in the cancers caused by the nonfunctioning of the BRCA1-BARD1 complex.

Functional SNPs in untranslated regions (UTR) predicted by FastSNP

The polymorphisms in the 3’ UTR affect gene expression during translation of mRNA while the polymorphisms in the 5’ UTR influence RNA half-life by altering polyadenylation [18,19]. The FastSNP (Function Analysis and Selection Tool for Single Nucleotide Polymorphisms) program was used to predict the functionally important SNPs in the 3’ and 5’ UTRs. That is a web server that efficiently identifies the functional SNPs. That prioritizes SNPs according to twelve parameters (phenotypic risks and functional effects), such as changes to the transcriptional level, pre-mRNA splicing, protein structure, etc. FastSNP is unique in its feature that the prediction of functional effects is always based on

| SNP IDs | Nucleotide Change | Amino Acid Change | PSIC SD |
|---------|------------------|------------------|--------|
| rs140254589 | A/G | D 102 N | 1.614 |
| rs144856889 | C/T | H 116 Y | 2.082 |
| rs184660818 | C/T | S 184 F | 1.998 |
| rs16852741 | A/G | S 186 G | 1.633 |
| rs38593305 | T/C | L 220 S | 1.804 |
| rs145009419 | A/G | E 223 G | 2.039 |
| rs151325889 | C/A | P 246 Q | 2.087 |
| rs138904906 | A/G | N 255 S | 1.736 |
| rs146235397 | T/C | I 258 T | 1.568 |
| rs148760338 | C/T | P 315 L | 2.299 |
| rs141350303 | T/G | C 362 G | 2.902 |
| rs2229571 | G/C | R 378 S | 1.79 |
| rs76824305 | T/G | V 422 G | 1.527 |
| rs137988817 | G/C | D 458 H | 2.064 |
| rs111350417 | T/C | V 477 A | 1.51 |
| rs149839922 | T/C | L 480 S | 1.885 |
| rs146946984 | G/A | R 565 H | 1.859 |
| rs75709313 | C/A | A 594 D | 1.863 |
| rs140642433 | T/C | C 628 R | 3.41 |
| rs4986841 | A/T | I 653 F | 1.718 |
| rs187590361 | A/G | N 663 S | 1.669 |
| rs111284953 | T/A | V 695 D | 1.879 |
| rs15121935 | A/T | D 710 V | 2.514 |
| rs140729292 | G/A | A 721 T | 1.268 |
| rs13389423 | C/T | S 728 F | 1.998 |
| rs76744638 | C/G | R 731 G | 2.27 |
| rs139785364 | C→T | R 751 W | 2.495 |

Figure 2. Sequence homology-based results from Sorting Intolerant from Tolerant (SIFT) server for SNPs (SIFT output is modified and depicted only the intolerant amino acid substitutions).
doi:10.1371/journal.pone.0043939.g002
the most up-to-date information. FastSNP extracts updated information from eleven external Web servers. FastSNP also provides project management services for registered users to store and export their candidate SNPs and update the SNPs putative functional effects by re-submitting the query [20].

The FastSNP search was performed by querying by gene symbol [BARD1]. Table 3 lists the SNPs in the UTRs and the intronic region. The SNP rs58253676 in the 3’ UTR may have splicing regulator and enhancer functions and may possibly be a splice site. Most importantly, the nucleotide change may have a medium-high (3–4) level of risk for being a splicing regulator and a low-medium (2–3) level of risk for enhancer functions. rs17489363 and rs17426219 in the 3’ UTR may alter the transcriptional binding site. In the intronic region, rs67822872 SNP, an intronic enhancer, may have a medium-high (3–4) level of risk upon nucleotide change.

Modeling of amino acid substitution effects due to nsSNPs on protein structure, Energy minimization and RMSD

(A) The closest related protein structures. By using the EMBL-EBI Web-based tool PDBsum, the BARD1 gene product-related protein structures were searched. Three related protein structures, namely 1JM7, 3C5R and 2NTE, were found to share 100% amino acid sequence similarity (Table 4). 1JM7 is a BRCAl-BARD1 complex. Chain B accounts for residues 26 to 122.

(B) Models of substituted amino acids and their minimized energy and RMSD

The I-Mutant 2.0 server was used to predict the change in protein structure stability due to mutations. The input option for this tool is the 3D structure of protein. The tool was developed and functional nsSNP was made and visualized as a comparison using SPDBV.

Energy minimization for all the models and their native structures was achieved using the NOMAD-REF Gromacs server. The Gromacs tool uses a force field for energy minimization. The total energy for all the mutant and native models after minimization is listed in Table 5. The total energies for the native structures of 1JM7, 3C5R and 2NTE are −5209.592 kJ/mol, −6174.53 kJ/mol and −12127.86 kJ/mol, respectively. Change in total energy due to mutation is noticeable in the 1JM7 mutant rs71579841 (Ala40Val), being −2218.149 kJ/mol. Change in total energy due to mutation is also noticeable in 2NTE mutants rs7644638 (Arg731Tyr) and rs159785364 (Arg751Try), being −11882.29 kJ/mol and −11881.31 kJ/mol, respectively. Interestingly, other mutant models had almost the same energy as their native structures.

RMSD is the measure of the deviation of the mutant structures from their native configurations. Higher the RMSD value, the more deviation between the two structures. Structure changes, in turn, affect functional activity. Among all the 16 mutants, rs144856889 (His116Tyr) had the highest RMSD (1.8039 Å), followed by rs137988817 (Asp458His) (1.1598 Å), rs140254589 (Asp102Asn), rs140729292 (Ala721Thr), rs140642433 (Cys628Arg), rs149839922 (Leu480Ser) and rs150121935 (Arg751Try). Higher the RMSD value, the more deviation between the two structures.

Prediction of change in stability due to mutation

The I-Mutant 2.0 server was used to predict the change in protein structure stability due to mutations. The input option for this tool is the 3D structure of protein. The tool was developed and

| SNP ID | Nucleotide Change | UTR/Intronic Position | Possible Functional Effect | Level of Risk |
|--------|------------------|-----------------------|---------------------------|---------------|
| rs58253676 | (>6 bp) | 3’ UTR | Splicing regulation | Very Low-Medium (2–3) |
| rs17489363 | A/G | 5’ UTR | Promoter regulation | Very Low-Medium (2–3) |
| rs17426219 | G/A | 5’ UTR | Promoter regulation | Very Low-Medium (2–3) |
| rs67822872 | -/A | Inton | Intrinsic enhancer | Medium-High (3–4) |

Table 3. List of SNPs intron and UTR (mRNA) predicted to be functionally significant by FastSNP.
BARD1

Mutant amino acids affect the domain structures of BARD1

Some of the extracted data for Table 5 is as follows:

| Molecules                  | RMSD (Å) | Total energy after energy minimization (kJ/mol) |
|---------------------------|----------|-------------------------------------------------|
| 1JM7 native-type structure|          | −5209.592                                        |
| 1JM7 Mutant 40 (rs71579841)| 0.1364   | −2218.149                                        |
| 1JM7 mutant 102 (rs140254589)| 0.7866   | −5389.294                                        |
| 1JM7 mutant 116 (rs144856889)| 1.0839   | −5646.582                                        |
| 3CSR native-type structure|          | −6174.53                                         |
| 3CSR mutant 458 (rs137988817)| 1.1598   | −6126.259                                        |
| 3CSR mutant 477 (rs111350417)| 0.1626   | −6166.61                                         |
| 3CSR mutant 480 (rs149839922)| 0.5496   | −6126.997                                        |
| 2NTE native-type structure|          | −12127.86                                        |
| 2NTE mutant 594 (rs75709313)| 0.2848   | −12146.148                                       |
| 2NTE mutant 628 (rs146642433)| 0.6725   | −11952.286                                       |
| 2NTE mutant 653 (rs4986841)| 0.2891   | −12192.765                                       |
| 2NTE mutant 663 (rs187590361)| 0.3793   | −12020.879                                       |
| 2NTE mutant 695 (rs111367604)| 0.4299   | −12263.969                                       |
| 2NTE mutant 710 (rs150121935)| 0.5399   | −12018.463                                       |
| 2NTE mutant 721 (rsrs140729292)| 0.696    | −12200.248                                       |
| 2NTE mutant 728 (rs13389423)| 0.4079   | −12134.148                                       |
| 2NTE mutant 731 (rs76746638)| 0.4724   | −11862.29                                         |
| 2NTE mutant 751 (rs139785364)| 0.1796   | −11881.313                                       |

**Table 5.** RMSD and total energy after energy minimization of native-structures of 1JM7, 3CSR and 2NTE and their mutant models.

doi:10.1371/journal.pone.0043939.t005

Mutant amino acids affect the domain structures of BARD1

The affected domains and the allelic frequency of corresponding nsSNPs are listed in Table 7. Only ankyrin ring and BRCT domains harbor the predicted deleterious mutations. All the mutations of 2NTE, except rs187590361 (Asn663Ser), were located in the BRCT domains of BARD1, whereas all the 35CR mutations were located in the ankyrin rings. Structural changes in BARD1 due to 2NTE mutations can be better understood in Figure 3.

One of the major purposes of genetics studies is to distinguish functionally neutral mutations from those that contribute to disease. About half of the known gene lesions accounting for human inherited disease involve amino acid substitutions. Hence, to identify the nsSNPs those affect protein functions and, in turn, manifest themselves as diseases are an important issue [22,23]. The functional effect of many nsSNPs may be neutral because natural selection will have removed mutations in essential positions. Using phylogenetic information with certain structural approaches is the basis of the assessment of these nsSNPs. Still, there is increasing evidence that the onset of many human diseases is due to mutations in the intronic regions of genes. Such mutations cause alterations in regulatory regions and the splicing process [24,25].

SNPs are widespread throughout the genome. This fact makes them a preferred choice as genetic markers in the research on diseases and their corresponding drugs [26]. More than 1 million SNPs have been reported so far. Many of them provide a large amount of information about relationships between individuals, populations and diseases. However, the large numbers of SNPs cause a challenge for biologists and bioinformaticians [26].

Studying associations between disease risk and these genetic variations using a molecular epidemiological approach has gained much attention from scientists. The number of reported and recorded SNPs is increasing. This huge number of SNPs makes it difficult for researchers to plan costly population-based genotyping. Due to a plethora of SNPs, it is difficult to choose the target SNPs that will most likely affect phenotypic functions and ultimately contribute to disease development [24,26,27].

Approximately 5–10% of breast and ovarian cancer predispositions are hereditary [28]. BRCA1 and BRCA2 being the most studied susceptibility genes. Mutations in BRCA1 are found in 40–50% of families with a high breast cancer risk. Among these mutation occurrences, 75–80% account for both breast and ovarian cancers [29]. Even so, a significant proportion of predisposition to breast cancer that is due to these genetic aberrations is still unanswered. This leads us to hypothesize that there must be involvement of some other susceptibility genes.
Table 6. Predictions of protein stability change due to mutations.

| Molecules Models     | Position of amino acid on protein Molecule | WT  | MT   | SVM2 Prediction Effect | DDG Value Prediction Kcal/mol | RI   | RSA  |
|----------------------|-------------------------------------------|-----|------|------------------------|-------------------------------|------|------|
| 1JM7 Mutant Models   |                                           |     |      |                        |                               |      |      |
| 1JM7 (rs71579841)    | 40                                        | A   | V    | Decrease               | -0.53                         | 3    | 0.0  |
| 1JM7 (rs140254589)   | 102                                       | D   | N    | Decrease               | -2.33                         | 9    | 20.8 |
| 1JM7 (rs144856889)   | 116                                       | H   | Y    | Increases              | -0.13                         | 0    | 74.2 |
| 3CSR Mutant Models   |                                           |     |      |                        |                               |      |      |
| 3CSR (rs137988817)   | 458                                       | D   | H    | Increases              | -0.26                         | 1    | 8.3  |
| 3CSR (rs111350417)   | 477                                       | V   | A    | Decreases              | -1.29                         | 8    | 0.0  |
| 3CSR (rs149839922)   | 480                                       | L   | S    | Decreases              | -2.15                         | 6    | 0.0  |
| 2NTE Mutant Models   |                                           |     |      |                        |                               |      |      |
| 2NTE (rs75709313)    | 594                                       | A   | D    | Decrease               | -1.25                         | 6    | 13.6 |
| 2NTE (rs140642433)   | 628                                       | C   | R    | Decrease               | -1.84                         | 7    | 4.3  |
| 2NTE (rs4986841)     | 653                                       | I   | F    | Decrease               | -0.51                         | 8    | 3.8  |
| 2NTE (rs187590361)   | 663                                       | N   | S    | Decrease               | -1.49                         | 8    | 10.2 |
| 2NTE (rs111367604)   | 695                                       | V   | L    | Decrease               | -0.7                          | 8    | 0.7  |
| 2NTE (rs150121935)   | 710                                       | D   | V    | Decrease               | -1.07                         | 4    | 59.0 |
| 2NTE (rs140729292)   | 721                                       | A   | T    | Decrease               | -1.02                         | 6    | 0.0  |
| 2NTE (rs13389423)    | 728                                       | S   | F    | Decrease               | -0.41                         | 3    | 6.8  |
| 2NTE (rs76744638)    | 731                                       | R   | G    | Decrease               | -0.88                         | 6    | 31.4 |
| 2NTE (rs139785364)   | 751                                       | R   | W    | Decrease               | 0.15                          | 7    | 37.6 |

For all the predictions, pH and temperature were selected as 7.0 and 25°C, respectively. WT: Wild type amino acid, MT Mutant type amino acid, ΔΔG: ΔG(New Protein)-ΔG(Wild Type) in Kcal/mol (ΔΔG<0: Decrease stability, ΔΔG>0: Increase stability), RI: Reliability index, RSA: Relative solvent accessible area.

doi:10.1371/journal.pone.0043939.t006

Therefore, we targeted the genes encoding proteins associated to BRCA1 for study.

In this study, we have examined the BARD1 gene to analyze and identify the deleterious and functional nsSNPs using in silico methods. BARD1 is one of the BRCA1-associated proteins and the two share closely related domain structures [30]. Both have an N-terminal zinc finger domain and a C-terminal BRCT domain which had been found in many proteins. In these proteins, the domains are involved in DNA repair and cell cycle regulation. Particularly, the zinc finger domain is functionally important in the formation of the BRCA1/BARD1 complex [31]. BARD1 contains three ankyrin repeats, which have been reported to be involved in transcription regulation when they are also present in other proteins [32]. Furthermore, the complex of the BARD1/ BRCA1 heterodimer and CstF-50 (cleavage stimulation factor subunit I) represses the polyadenylation machinery, presumably to prevent inappropriate mRNA processing at sites of DNA repair [33]. BARD1 also regulates the nuclear translocation of BRCA1 by preventing its export [34]. The involvement of BARD1 in TP53-independent apoptotic signaling has been reported previously. It can also function independent of BRCA1. BARD1 interacts with ankyrin repeats of BCL3 and thus is likely to modulate the activities of the transcription factor NFκB [35,36].

Hence, nsSNP variation which causes a change in amino acid composition may result in the alteration of structural domains. For example, if there is an alteration in the ring finger domain, it may hinder BRCA1/BARD1 complex formation, reduce the stability of BRCA1, and change the polyadenylation process of mRNAs. Nevertheless, the alteration of ankyrin repeats or the BRCA1 C-terminal (BRCT) domain may lead to abnormal transcriptional or cell cycle regulation, respectively.

SIFT predicted 11 nsSNPs as deleterious, and PolyPhen predicted 27 nsSNPs as deleterious. Among them, only 5 nsSNPs were common (Table 1 and 2). They are rs4986841 (Ile653Phe), rs187590361 (Asn663Ser), rs111367604 (Val695Leu), rs13389423 (Ser728Phe) and rs139785364 (Arg751Trp). rs111367604 (Val695Leu) has been found to be associated with predisposition to breast, ovarian and uterine cancers [12], which is in agreement with our findings. SNPs in UTRs may alter transcription binding sites, splicing sites and polyadenylation of mRNAs [18,19]. The SNPs rs58253676 in the 3' and rs17489363 and rs17426219 in the 5' UTRs are predicted to be involved in splice site regulation (Table 3). None of them have been studied so far in terms of their functional effects in any population. There were only three structures found in the Protein Data Bank, 1JM7, 3CSR and 2NTE, which shared 100% similarity with the BARD1 amino acid sequence (Table 4). Energy minimization, RMSD calculation and modeling of mutants were performed on the above-mentioned structures. The free energies of the mutant models of 1JM7 rs71579841 (Ala40Val), C35R rs137988817 (Asp458His), C35R rs149839922 (Leu480Ser) and 2NTE rs140642433 (Cys628Arg) and rs76744638 (Arg731Gly) decreased markedly. The minimum RMSD was calculated to be 0.1364 for 1JM7 rs71579841 (Ala40Val), while the maximum RMSD was calculated to be 2.15 for 1JM7 rs14856889 (His116Tyr) and 1.5998 for C35R rs137988817 (Asp458His). RMSDs in the range of 0.7866 for rs140254589 (Asp102Asn) and 0.1796 for rs139785364 (Arg751Trp) (Table 5) were observed in these mutants. All five nsSNPs which were predicted to be deleterious by both SIFT and PolyPhen were found to be involved in decreasing protein stability.
found in the BRCT domain of BARD1. This finding suggests that these four nsSNPs may decrease protein stability, hinder transcriptional regulation, and interfere with cell cycle regulation [31].

BARD1 SNPs G1743C (Cys557Ser), T2006C (Cys645Arg) and G2355A (Ser761Asn) have been identified to be associated with ovarian cancer, breast and ovarian cancer and breast cancer, respectively [9,12]. A Finnish population study reported three synonymous and four nsSNPs. The nsSNPs were C1207G (Ser378Arg), G1592A (Val507Mat), C2045T (Arg658Cys) and G1743C (Cys557Ser). Only G1743C (Cys557Ser) was found associated with breast cancer predisposition in that study [10]. The same SNP was found associated with risk of single and multiple primary breast cancer [37]. Pro24Ser and C1207G (Ser378Arg)

---

**Table 7. ns SNPs found in different motifs and domains of BARD1 protein.**

| Structural domains | Mutants            | Amino Acid Position | Wild Type | Mutant | Allelic Frequency |
|--------------------|--------------------|---------------------|-----------|--------|------------------|
| Ankyrin Repeat     | 3CSR (rs137988817) | 458                 | D         | H      | 0.00             |
|                    | 3CSR (rs111350417) | 477                 | V         | A      | 0.5              |
|                    | 3CSR (rs149839922) | 480                 | L         | S      | NA               |
| BRCT domain        | 2NTE (rs75709313)  | 594                 | A         | D      | 0.05             |
|                    | 2NTE (rs140642433) | 628                 | C         | R      | 0.0              |
|                    | 2NTE (rs4986841)   | 653                 | I         | F      | 0.01             |
|                    | 2NTE (rs111367604) | 695                 | V         | L      | 0.05             |
|                    | 2NTE (rs150121935) | 710                 | D         | V      | 0.0              |
|                    | 2NTE (rs140729292) | 721                 | A         | T      | 0.0              |
|                    | 2NTE (rs13389423)  | 728                 | S         | F      | 0.019            |
|                    | 2NTE (rs76744638)  | 731                 | R         | G      | 0.5              |

---

Figure 3. A comparison of amino acid substitutions due to nsSNPs, rs4986841 (Ile653Phe), rs111367604 (Val695Leu), rs13389423 (Ser728Phe) and rs139785364 (Arg751Trp). Figure shows the differences of structure and electron cloud density between native and mutant models BARD1 Protein (PDB ID: 2NTE). Models were generated by using SPDBV (v4.0).

doi:10.1371/journal.pone.0043939.t007
may jointly contribute to the susceptibility of breast cancer. Their heterozygote and homozygote are associated with decreased risk of breast cancer [30]. Recently, G1743C (Cys557Ser) has been reported for no association with the predisposition of familial breast cancer in an Australian population based case control study [39]. In a cohort based study of a French population, nine common SNPs of BARD1 including G1743C (Cys557Ser) were not shown any role as modifier of risk in BRCA1/2 mutant carriers [40]. Furthermore, BARD1 SNPs rs6435862 and rs5767816 and some known common nsSNPs have been found significantly associated with the aggressive neuroblastoma [41]. During the last decade, approximately 12 nsSNPs have been studied in different populations for their association with the predisposition to various female cancers. Some of them are recorded in the dbSNP database for the BARD1 gene (http://www.ncbi.nlm.nih.gov/gene/530). They are rs28997576 (Cys557Ser), rs146946984 (Arg565His), rs34744268 (Cys645Arg), rs111367604 (Val695Leu) and rs142155101 (Ser761Asn) [9,12]. rs111367604 (Val695Leu) has been predicted to be deleterious by SIFT and PolyPhen only. Contrarily, among nsSNPs predicted damaging by SIFT and/or PolyPhen rs142155101 (Ser761Asn) [9,12]. rs111367604 (Val695Leu) has been predicted by SIFT to be deleterious only. There is a need to update the dbSNP database accordingly.

Conclusions

This study concludes that with the available bioinformatics tools and the data present in the dbSNP database, four nsSNPs are deleterious and likely reduce protein stability. These nsSNPs are rs4986841 (Ile653Phe), rs111367604 (Val695Leu), rs13389423 (Ser728FPhe) and rs139785364 (Arg751Trp). Their presence in the BARD1 protein “Q99728” was submitted with the position of amino acid variants. PolyPhen classifies the SNPs as “benign,” “possibly damaging” or “probably damaging” based on specific site-function conservation among mammals, as well as their location in the three-dimensional structure of the protein molecule. The term “damaging” used by PolyPhen reflects the mutations affecting protein structure and not the loss or gain of function [50]. The protein identifier from the UniProt database for the BARD1 protein “Q99728” was submitted with the position of variation along with the wild type and mutant amino acids. PolyPhen then calculated PSIC scores for each of the two variants based on three parameters, namely, (i) sequence-based characterization of the substitution site, (ii) profile analysis of homologous sequences and (iii) mapping of a substitution site to a known three-dimensional protein structure. The PSIC score difference between the two variants elucidates the amount of functional consequences that the nsSNP exerts. The PSIC score difference is regarded to be directly proportional to the impact of a particular amino acid substitution [51].

Structural homology-based prediction of functional consequences of coding nsSNPs by using PolyPhen

The ability of the protein to interact with other molecules or to have different functions depends upon its tertiary structure [47,48]. Therefore, analysis of damaged coding nsSNPs at the structural level is necessary to understand the activity of the protein. The Polyphen server (http://genetics.bwh.harvard.edu/pph/) was used to study the functional consequences of nsSNPs [17,49]. The Polyphen server requires the protein sequence or a SWALL database ID or accession number as well as the sequence position of amino acid variants. PolyPhen classifies the SNPs as “benign,” “possibly damaging” or “probably damaging” based on site-specific sequence conservation among mammals, as well as their location in the three-dimensional structure of the protein molecule. The term “damaging” used by PolyPhen reflects the mutations affecting protein structure and not the loss or gain of function [50]. The protein identifier from the UniProt database for the BARD1 protein “Q99728” was submitted with the position of variation along with the wild type and mutant amino acids. PolyPhen then calculated PSIC scores for each of the two variants based on three parameters, namely, (i) sequence-based characterization of the substitution site, (ii) profile analysis of homologous sequences and (iii) mapping of a substitution site to a known three-dimensional protein structure. The PSIC score difference between the two variants elucidates the amount of functional consequences that the nsSNP exerts. The PSIC score difference is regarded to be directly proportional to the impact of a particular amino acid substitution [51].
Modeling of protein structure amino acid substitutions caused by nsSNPs, energy minimization and calculating the RMSD

(A) Finding the closest related protein. The EMBL-EBI Web-based tool PDBsum [http://www.ebi.ac.uk/pdbsum/] was used to find the proteins related to the BARD1 gene. PDBsum provides an at-a-glance overview of every macromolecular structure deposited in the Protein Data Bank (PDB). It performs a FASTA search against all sequences in the protein data bank (PDB) to obtain a list of the closest matches. The FASTA sequence of the BARD1 protein was provided in the query space. We selected only the three closest matches, namely the solution structure of the BRCA1/BARD1 ring-domain heterodimer (PDB ID 1J7M) [8], the crystal structure of the BARD1 ankyrin repeat domain (PDB ID 3C5R) [54] and the crystal structures of the BARD1 BRCT domains (PDB ID 2NTE) [53].

(B) Modeling amino acid substitution, energy minimization and RMSD calculation. Swiss-PDBViewer (v4.04) was used to generate the mutated models of each of the selected PDB entries for the corresponding amino acid substitutions. Swiss-PDBViewer allows browsing through a rotamer library to exchange amino acids. A “mutation tool” was used to replace the native amino acid with a new one. The mutation tool facilitates the replacement of the native amino acid by the “best” rotamer of the new amino acid. The “.pdb” files were saved for all the models. The NOMAD-Ref Gromacs server was used to perform energy minimization for all the native and mutated models of 1J7M, 3C5R and 2NTE. The NOMAD-Ref Server makes use of Gromacs using force fields for energy minimization according to the steepest descent, conjugate gradient or L-BFGS methods [56]. The conjugate gradient method was utilized in this study. RMSDs between the native structure and each mutant were calculated using YASARA [57].

Predicting the change in stability due to mutation

To predict the change in the stability of the protein upon mutation, a support vector machine (SVM)-based tool server, I-Mutant 2.0, was used. This tool automatically predicts protein stability changes upon single point mutations. Prediction can be performed using either protein structure or sequence. I-Mutant 2.0 can be used both as a classifier for predicting the sign of the protein stability change upon mutation and as a regression estimator for predicting the related change in Gibbs-free energy ($\Delta$G) [21]. Scanning of nsSNPs for their position in different protein domains

To find the nsSNPs and the amino acid changes they may cause in different domains of the protein structures, the Prosit-ExPaSy tool was used [http://prosite.expasy.org/]. The UniProtKB ID was provided for the query column, and the UniProt database was searched for motifs and domains of BARD1. The results were obtained as the categorized sequence of amino acids with their respective positions in the protein subsequences and domains.

Author Contributions

Conceived and designed the experiments: AAA TNH BLG. Performed the experiments: TNH NAS. Analyzed the data: AAA TNH GS. Wrote the paper: AAA TNH BLG.

References

1. Luu TD, Rusu AM, Walter V, Rapp R, Mudunur, et al. (2012) MSV3d: database of human MiSense Variants mapped to 3D protein structure. Database (Oxford); 2012:bas018. Print 2012.
2. Chasman D, Adams RM (2001) Predicting the functional consequences of non-synonymous single nucleotide polymorphisms: structure-based assessment of amino acid variation. J Mol Biol 307:603–706.
3. Lander ES (1996) The new genomics: global views of biology. Science 274:536–539.
4. Barroso I, Rajagopal P, Hoyt DW, King MC, Klevit RE (2003) Structure of a BRCA1-BARD1 heterodimeric RING-RING complex. Nat Struct Biol 8:833–837.
5. Ghinemili C, Sensi E, Pescitelli S, Brunetti IM, Conte P-F, et al. (2002) Germ-line mutations of the BRCA1-associated ring domain (BARD1) gene in breast and ovarian cancer. J Med Genet 40:415–420.
6. Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, et al. (1994) Estrogen resistance caused by the mutation in the estrogen-receptor gene in a man. N Engl J Med 331:1056–1061.
7. Sauer MK, Amuthil R (2005) Identification and characterization of missense alterations in the BRCA1 associated RING domain (BARD1) gene in breast and ovarian cancer. J Med Genet 42:635–638.
8. Irminger-Finger I, Leung WC (2002) BRCA1-dependent and independent functions of BARD1. Int J Biochem Cell Biol 34:502–507.
9. Brouwer PS, Rajagopal P, Hoyt DW, King MC, Klevit RE (2003) Structure of a BRCA1-BARD1 heterodimeric RING-RING complex. Nat Struct Biol 8:833–837.
10. Karpipinen SM, Heikkinen K, Rapakko K, Winquist R (2004) Mutation screening of the BARD1 gene: evidence for involvement of the Cys537Ser allele in early onset breast cancer, and independent association with breast and ovarian cancer. Hum Mutat 23:225–235.
11. Ellsworth RE, Decewicz DJ, Shriver CD, Ellsworth DL (2010) Breast cancer in hereditary susceptibility to breast cancer. J Med Genet 47:e114.
12. Thai TH, Du F, Tsan JT, Jin Y, Phung A, et al. (1998) Bowcock AM. Mutations in the cancer and steroid hormone study. Am J Hum Genet 48:232–242.
13. Ishitobi M, Miyoshi Y, Hasegawa S, Egawa C, Tamaki Y, et al. (2003) Identification of the closest matches. The FASTA sequence of the BARD1 protein was provided in the query space. We selected only the three closest matches, namely the solution structure of the BRCA1/BARD1 ring-domain heterodimer (PDB ID 1J7M) [8], the crystal structure of the BARD1 ankyrin repeat domain (PDB ID 3C5R) [54] and the crystal structures of the BARD1 BRCT domains (PDB ID 2NTE) [53].
14. Neel BC, Ayers K, Hare BC, et al. (2009) The role of the Cys537Ser allele in early onset breast cancer, and independent association with breast and ovarian cancer. Hum Mutat 23:225–235.
15. Bhagwat M (2010) Searching NCBI’s dbSNP database. Curr Protoc Bioinformatics Chapter 1 Unit 1.19
16. Ng PC, Henikoff S (2003) SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res 31:3812–3814.
17. Ramensky V, Bork P, Sunyaev S (2002) Human non-synonymous SNPs: server and survey. Nucleic Acids Res 30:3894–900.
18. Sandberg R, Nelson JR, Sarma A, Sharp PA, Burge CB (2008) Prolificating cells express mRNAs with shortened 3’ untranslated regions and fewer microRNA target sites. Science 320:1643–1647.
19. Wang G, Guo X, Floros J (2005) Differences in the translation efficiency and mRNA stability mediated by 5’UTR splice variants of human SP-A1 and SP-A2 genes. J Appl Physiol 98:497–508.
20. Yuan HY, Chiao J, Tseng WH, Liu CH, Liu CK, et al. (2006) FASTSNP: an always up-to-date and extendable service for SNP function analysis and prioritization. Nucleic Acids Res 34(Web Server issue):W635–41.
21. Caporossi E, Fasidi P, Casadio R (2005) 1Mmutation2.0: predicting stability changes upon mutation from the protein sequence or structure. Nucleic Acids Res 33:W306–W310.
22. Reva B, Antipin Y, Sander C (2011) Predicting the functional impact of protein mutations: application to cancer genomics. Nucl Acids Res 39:118. DOI:10.1093/nar/gkr407
23. Smith C (2005) Genomics: SNPs and human disease. Nature 435:993. doi:10.1038/435993a.
24. Doss CG, Sethumadhavan R (2009) Investigation on the role of nsSNPs in HNPC genes-a bioinformatics approach. J Biomed Sci 16:42.
25. Ng PC, Henikoff S (2003) SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res 31:3812–3814.
26. Doss CG, Sethumadhavan R (2009) Investigation on the role of nsSNPs in HNPC genes-a bioinformatics approach. J Biomed Sci 16:42.
27. Ng PC, Henikoff S (2003) SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res 31:3812–3814.
28. Doss CG, Sethumadhavan R (2009) Investigation on the role of nsSNPs in HNPC genes-a bioinformatics approach. J Biomed Sci 16:42.
29. Doss CG, Sethumadhavan R (2009) Investigation on the role of nsSNPs in HNPC genes-a bioinformatics approach. J Biomed Sci 16:42.
30. Doss CG, Sethumadhavan R (2009) Investigation on the role of nsSNPs in HNPC genes-a bioinformatics approach. J Biomed Sci 16:42.
31. Doss CG, Sethumadhavan R (2009) Investigation on the role of nsSNPs in HNPC genes-a bioinformatics approach. J Biomed Sci 16:42.
32. Doss CG, Sethumadhavan R (2009) Investigation on the role of nsSNPs in HNPC genes-a bioinformatics approach. J Biomed Sci 16:42.
33. Doss CG, Sethumadhavan R (2009) Investigation on the role of nsSNPs in HNPC genes-a bioinformatics approach. J Biomed Sci 16:42.
34. Doss CG, Sethumadhavan R (2009) Investigation on the role of nsSNPs in HNPC genes-a bioinformatics approach. J Biomed Sci 16:42.
35. Doss CG, Sethumadhavan R (2009) Investigation on the role of nsSNPs in HNPC genes-a bioinformatics approach. J Biomed Sci 16:42.
31. Morris JR, Keep NH, Solomon E (2002) Identification of residues required for the interaction of BARD1 with BRCA1. J Biol Chem 277:2382–2386.
32. Sedgwick SG, Smerdon SJ (1999) Identification of BARD1 as mediator between proapoptotic stress and p53-dependent apoptosis. Trends Biochem Sci 24:311–316.
33. Kleiman FE, Manley JL (2001) The BARD1-CstF-50 interaction links mRNA 3' end formation to DNA damage and tumor suppression. Cell 104:743–753.
34. Fabbro M, Rodriguez JA, Baer R, Henderson BR (2002) BARD1 induces BRCA1 intranuclear foci formation by increasing RING-dependent BRCA1 nuclear import and inhibiting BRCA1 nuclear export. J Biol Chem 277:21315–21324.
35. Irminger-Finger I, Leung WC, Li J, Dubois-Dauphin M, Harb J, et al. (2001) Identification of BARD1 as mediator between proapoptotic stress and p53-dependent apoptosis. Mol Cell 8:1255–1266.
36. Dechend R, Hirano F, Lehmann K, Heissmeyer V, Ansieau S, et al. (1999) The Bcl-3 oncoprotein acts as a bridging factor between NF-kappaB/Rel and nuclear co-regulators. Oncogene 18:3316–3323.
37. Stacey SN, Sulem P, Johannsson OT, Helgason A, Gudmundsson J, et al. (2006) The BARD1 Cys557Ser variant and breast cancer risk in Iceland. PLoS Med 3:e217.
38. Hou WK, Xu YX, Yu T, Zhang L, Zhang WW, et al. (2007) Adipocytokines and breast cancer risk. Chin Med J (Engl) 120:1592–1596.
39. Johnatty SE, Beesley J, Chen X, Hopper JL, Southey MC, et al. (2009) The BARD1 Cys557Ser polymorphism and breast cancer risk: an Australian case-control and family analysis. Breast Cancer Res Treat 111:505–509.
40. Spurdle AB, Marquart L, McGuffog L, Healey S, Sinilnikova O, et al. (2011) Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev 20:1032–1038.
41. Capasso M, Devoto M, Hou C, Asgharzadeh S, Glessner JT, et al. (2009) Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. Nat Genet 41:718–723.
42. Zhou X, Han S, Wang S, Chen X, Dong J, et al. (2009) Polymorphisms in HPV E6/E7 protein interacted genes and risk of cervical cancer in Chinese women: a case-control analysis. Gynecol Oncol 114:527–533.
43. Ryu GM, Song P, Kim KW, Oh KS, Park KJ, et al. (2009) Genome-wide analysis to predict protein sequence variations that change phosphorylation sites or their corresponding kinases. Nucleic Acids Res 37:1297–1307.
44. Gorringe KL, Choong DY, Visvader JE, Lindeman GJ, Campbell IG (2008) BARD1 variants are not associated with breast cancer risk in Australian familial breast cancer. Breast Cancer Res Treat 111:305–309.
45. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, et al. (2001) dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 29:308–311.
46. Dutta S, M Berman H, F Bluhm W (2007) Using the tools and resources of the RCSB protein data bank. Curr Protoc Bioinformatics Dec:Chapter 1:Unit1.9.
47. Hasan TN, Grace BL, Masoodi TA, Shafi G, Ahshtari AA, et al. (2011) Affinity of estrogens for human progesterone receptor A and B monomers and risk of breast cancer: a comparative molecular modeling study. Adv Appl Bioinform Chem 4:29–36.
48. Ahshtari AA, Hasan TN, Syed NA, Shafi G (2011) Predicting the possibility of two newly isolated phenethyl ring containing compounds from Aristolochia manshurienensis as CDK2 inhibitors. Bioinform 7:334–338.
49. Adhuhwi IA, Schmidt S, Polshik I, Ramesny VE, Gerasimova A, et al. (2010) A method and server for predicting damaging missense mutations. Nat Methods 7:240–249.
50. Boyko AR, Williamson SH, Irlap AR, Degenhardt JD, Hernandez RD, et al. (2008) Assessing the evolutionary impact of amino acid mutations in the human genome. PLoS Genet 4:e1000083.
51. Rajaee Karan R, Sudhindarossa C, Doss CG, Sethumadhavan R (2007) Identification and in silico analysis of functional SNPs of the BRCA1 gene. Genomics 90:447–452.
52. Prokunina I, Alarcon-Riquelme ME (2004) Regulatory SNPs in complex diseases: their identification and functional validation. Expert Rev Mol Med 6:1–15.
53. Prokunina I, Castillejo-Lopez C, Oberg F, Gunnarsson I, Berg L, et al. (2002) A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet 32:666–669.
54. Fox D III, Le Trong I, Rajagopal P, Brzovic PS, Sankamp RE, et al. (2008) Crystal structure of the BARD1 ankyrin repeat domain and its functional consequences. J Biol Chem 283:21179–21186.
55. Birrane G, Varma AK, Soni A, Ladas JA (2007) Crystal structure of the BARD1 BRCT domains. Biochemistry 46:7706–7712.
56. Lindahl E, Anzara C, Koehl P (2006) NOMAD-Ref: visualization, deformation and refinement of macromolecular structures based on all-atom normal mode analysis. Nucleic Acids Res 34:W52–W56.
57. Krieger E, Koznaim G, Vriend G (2002) Increasing the precision of comparative models with YASARA NOVA-a self-parameterizing force field. Proteins 47:393–402.